Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Potential New Revenue Stream: AbbVie’s BOTOX Cosmetic Application Progress and Market Implications

Exploring the implications of FDA's acceptance of BOTOX for masseter muscle prominence on AbbVie's financial outlook.

Aug 9, 2026
Pharmaceutical

Spectral Medical (TSX: EDT) Announces Q2 2026 Results and FDA Progress: A Game Changer for Investors

Spectral Medical's Q2 2026 results and FDA advancements could redefine shareholder value and commercialization prospects.

Aug 9, 2026
Pharmaceutical

iRhythm's Strong Q2 Earnings and Vital Connect Acquisition: A Sign of Growth

iRhythm's Q2 earnings beat and acquisition of Vital Connect signal promising growth in wearable health tech.

Aug 8, 2026
Pharmaceutical

Eli Lilly's Next-Gen Weight-Loss Drug Filing: A Game Changer for Investors

Eli Lilly's FDA filing for a new weight-loss drug could reshape the market landscape and challenge competitors like Novo Nordisk.

Aug 8, 2026
Pharmaceutical

NRx Pharmaceuticals Moves Closer to Launching Preservative-Free Ketamine

NRx Pharmaceuticals' ANDA for preservative-free ketamine passes FDA first-cycle review, signaling significant market potential.

Aug 7, 2026
Pharmaceutical

Moderna's mRNA Flu Vaccine Approval: A Milestone with Market Implications

Moderna's recent FDA approval for its mRNA flu vaccine marks a significant step, yet market sentiment remains cautious.

Aug 7, 2026
Pharmaceutical

Harrow's Strategic Acquisition of TYRVAYA: A Game-Changer for Ophthalmic Treatments

Harrow's acquisition of TYRVAYA positions it as a key player in ophthalmic treatments, offering potential revenue growth.

Aug 6, 2026
Pharmaceutical

Tarsus Pharmaceuticals Expands Eye Care Pipeline with Alkeus Acquisition

Tarsus Pharmaceuticals strengthens its eye care portfolio by acquiring Alkeus Pharmaceuticals, focusing on gildeuretinol, a potential Starga…

Aug 6, 2026
Pharmaceutical

Moderna's Groundbreaking mRNA Flu Vaccine Approval: A New Chapter in Vaccination

Moderna's mFLUSIVA, the first FDA-approved mRNA flu vaccine, is set to reshape the vaccination landscape and boost investor confidence.

Aug 6, 2026
Pharmaceutical

Harrow's Acquisition of TYRVAYA: A Game Changer for Dry Eye Treatment

Harrow Pharmaceuticals acquires TYRVAYA, the first FDA-approved nasal spray for dry eye disease, reshaping the market landscape.

Aug 6, 2026
Pharmaceutical

Moderna's Historic mRNA Influenza Vaccine Approval: What It Means for Investors

Moderna's mFLUSIVA approval marks a pivotal moment for the company and its investors, showcasing its evolution beyond COVID-19.

Aug 6, 2026
Pharmaceutical

Arrowhead Pharmaceuticals: Strategic Move with FDA Priority Review Voucher

Arrowhead Pharmaceuticals secures FDA Priority Review Voucher for plozasiran, aiming to expedite its supplemental NDA filing.

Aug 5, 2026